EXOPHARM LIMITED(EX1)

name changed to Tryptamine Therapeutics Ltd

The company releases an Appendix 3G.

The company releases an application for quotation of securities.

The company releases its notice of proposed issue of securities.

The company lodges its Quarterly Activities Report and Appendix 4C.

The share register of Shares and Options has been updated to a ratio of 2.5:1 pursuant to the consolidation of capital as outlined in the Appendix 3A.3 dated 13 March 2024 and as approved by Shareholders of the Company on 11 April 2024. The share register of Shares and Options has been updated to a ratio of 2.5:1 pursuant to the consolidation of capital as outlined in the Appendix 3A.3 dated 13 March 2024 and as approved by Shareholders of the Company on 11 April 2024.

The company releases the results of its 2024 general meeting.

The following documents in relation to its re-compliance priority offer (Priority Offer) have been despatched today to Eligible Shareholders, being EX1 Shareholders as at 7:00pm AEDT on Thursday, 14 March 2024 and who have a registered address on the Company share registry in Australia, New Zealand, Belgium and the United States of America: Letter of Access to the Prospectus; and Personalised Priority Offer application form.

The company releases an addendum to the previously sent notice of meeting. The Directors have resolved to amend the Notice by: changing the terms of the Quoted Options to reflect these Options will be unquoted; including details of a newly granted ASX waiver from Listing Rule 10.13.5; replacing the use of funds tables included in section 4.18; and replacing the Pro Forma Balance Sheet included at Schedule 4.

The company releases an updated notice of proposed issue of securities.

The company releases a replacement prospectus.

The company releases a notice of proposed issue of securities.

The company releases a prospectus for an offer of up to 325,000,000 Shares at an issue price of A$0.02 each to raise up to A$6,500,000 (before costs).

Tryp's securityholders approve Arrangement Agreement on 8 March 2024. Supreme Court of British Columbia issued its Final Order approving the Arrangement Agreement on 11 March 2024.

The company releases a notice of consolidation. Shareholders will get 2 for every 5 presently owned.

The company releases the following: 2024 General Meeting Letter of Access, Notice of Meeting and Proxy. The company's 2024 General Meeting of Shareholders will be held at 2.00 PM AEST on Thursday, 11 April 2024 at the offices of Bio101 Financial Advisory Pty Ltd, Suite 201, 697 Burke Road, Camberwell VIC 3124 and as a virtual meeting.

Exopharm signs a Binding Arrangement Agreement to acquire Tryp Therapeutics Inc. a Canadian-based clinical-stage biotechnology company by way of a Canadian plan of arrangement. Tryp is developing an IV infusion of psilocin which addresses many of the current limitations associated with orally administered psilocybin used by the majority of competitors in the field. Tryp's lead programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Exopharm intends to raise up to A$6.5 million (before costs) via a public offer to support the research and development of Tryp's lead programs. Tryp has undertaken an interim capital raise by way of a convertible note of A$3.39 million, which, subject to compliance with the Listing Rules will convert into 169,500,000 Shares in the Company on a post-Consolidation basis, with 135,600,000 free attaching options. Exopharm to change its name to "˜Tryptamine Therapeutics Limited' and re-comply with Chapters 1 and 2 of the ASX Listing Rules as a clinical-stage biotechnology company focused on the research and development of transformative medicine with known safety profiles to diseases with no effective first-line treatments.

The company lodges its Appendix 4D and Half Year Report for period 31 December 2023.

The company lodges its Quarterly Activities Report and Appendix 4C.

The company releases a notification regarding unquoted securities.

The company has undergone some essential changes over the past 12 months "“ most notably building up cash reserves whilst reducing operating costs significantly. Over the past months, the Board have been investigating ways to increase shareholder value. Whilst seeking to realise the potential financial value of the company's exosome technology intellectual property, the Board is also seeking a transaction that could result in a material change in the company's activities. Founding CEO Dr Ian Dixon and Business Services Manager Dr Gregor Lichtfuss have worked with directors Mr Mark Davies and Mr Clarke Barlow to implement the strategy of the Board, successfully reducing operating costs, selling surplus equipment and finalising recent patent activities. Dr Dixon is also seeking to realise the potential value of the company's exosome technology intellectual property, including the patented LEAP technology, through ongoing discussions with other parties. The Board is working hard to bring the potential transaction to shareholders and have the company's shares recommence trading. Meanwhile, the Company is minimising nonessential costs.

The company releases the results of its meeting.

The company releases its 2023 AGM Chair Address.

The company lodges its Quarterly Activities Report and Appendix 4C.

The company's 2023 AGM will be held at 12.00pm (AEDT) on Thursday, 23 November 2023 at Level 5, 126 Phillip Street, Sydney, NSW 2000 and as a virtual meeting.

The securities of Exopharm Limited will be suspended from quotation immediately, pending the receipt of an announcement regarding a transaction that could result in a change of its activities. EX1's securities will remain suspended until it has either complied with Chapters 1 and 2 of the Listing Rules under Listing Rule 11.1.3, or provided ASX with sufficient information to satisfy ASX that it should not exercise its discretion under Listing Rule 11.1.2 to require the transaction to be conditional on approval by EX1's ordinary security holders, and under Listing Rule 11.1.3 to require EX1 to recomply with Chapters 1 and 2 of the Listing Rules.

listed entity carried for record purposes only